Our Promise: One pill, one bottle, one prescription, one refill, one dispensing fee, one co-pay, once-a-day.
Chief Operations Officer
Dr. Gregory has held senior positions with numerous pharmaceutical companies over the last two decades. As Senior Vice President of Business Development for a top bio-capital enterprise, his efforts led to the development of several new US pharmaceutical companies.
Dr. Gregory developed three new pharmaceutical businesses for a leading contract research organization, to include a specialty pharma division, an international R&D joint venture, as well as a research based development arm. Dr. Gregory spent his early career with SmithKline Beecham in the US and Europe in sales and marketing, government relations and international business development. Following a tour in the US Marine Corps, Daniel Gregory completed his doctoral work at Columbia University.
Chief Financial Officer
Mr. Stimits has 15-years’ experience in the pharmaceutical industry.
Mr. Stimits has served as the Vice President of Business Development and Licensing at a leading life sciences firm engaged in proprietary drug development, asset management and private equity.
During this time, Roy led numerous successful in-licensing ventures from Europe and Asia. Prior to this, Roy served in Finance and Corporate Business Development at a global pharmaceutical research organization. During this time, the company successfully expanded its banking facility, acquired five marketed Rx products, and launched a profitable specialty pharmaceutical company. Roy has a Bachelor of Science degree from Lamar University and a Master of Financial Management degree from the University of Dallas.
Chief Medical Officer
Frank A. Snyder, M.S., M.D.
Dr. Snyder is one of the originators of the CardiaPill concept.
Dr. Snyder is the current Founder/Owner of Wilmington Internal Medicine. He was the former Director of the Pender Memorial Hospital Emergency Room and was former Chief of Medicine at Cape Fear Memorial Hospital. Dr. Snyder is a well respected personality in the biotech/pharmaceutical industry and has served as a lecturer/consultant for many big pharmaceutical companies including Pfizer, Kos, Glaxo Welcome, Sankyo, Wyeth, Monarch, Novartis, Liposcience, Tanabe and AAI Pharma, as well as several biotechnology investment groups.
Vice President Global Regulatory Affairs & Quality Assurance
Wayne L. Whittingham
Wayne has 30+ years of pharmaceutical product development experience.
His focus for the last 20 years has been on regulatory affairs and quality assurance. His regulatory experience encompasses developing and executing strategic regulatory plans, interacting with FDA and international regulatory agencies, and writing, preparing, assembling and submitting all regulatory documentation and communications.
In his various roles for previous companies, Wayne has provided regulatory guidance to multidisciplinary project teams and lead tactical discussions for R&D product development teams. Wayne has also worked closely with legal staff on the review of licenses, contracts and agreements. Wayne has served as a key member on committees responsible for the review and approval of product promotional, sales and marketing materials.
Wayne’s experience has been critical in facilitating communication and developing working relationships with FDA, DEA and USP as well as with Health Canada, EMEA and other international regulatory agencies. His therapeutic expertise includes Ophthalmic, Cardiovascular, Metabolic and Endocrine, CNS (including Analgesics), Gastrointestinal, Respiratory and Oncology. He has extensive direct experience with Drugs (New Drugs, Generics and Orphan Drugs), Biologics and Devices.
Wayne’s prior experience includes leadership roles in emerging through “big pharma” companies, start-up biotechs and global CROs.